ERBB2 and neoplasm: A recent study that included 40 patients with HER2 + metastatic breast cancer who were treated with trastuzumab, showed that increased numbers of iNOS + M1-like macrophages and CD8 + T-cells within the tumour was associated with improved survival, indicating that responses to trastuzumab can be affected by the immunological status of the tumour24.